Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy
Opus Genetics, Inc. (NASDAQ: IRD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024
Opus Genetics, Inc. (NASDAQ: IRD) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $8.00 price target on the stock.
Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update